Hair Aging in Different Races and Ethnicities.

Aging is an unavoidable biological process with many influencing factors, accounting for a multitude of visible manifestations on the hair as well as the skin. As the population ages while becoming more diverse, it is increasingly important to better understand the hair aging process. A literature search was performed to review what is known about changes in hair structure over time, focusing on the differences in hair aging according to ethnic background.

Leprosy: Treatment and management of complications.

In the second article in this continuing medical education series, we review the treatment of leprosy, its immunologic reactions, and important concepts, including disease relapse and drug resistance. A fundamental understanding of the treatment options and management of neuropathic sequelae are essential to reduce disease burden and improve patients' quality of life.

Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series.

Background: Bullous pemphigoid (BP) is an autoimmune blistering disorder occurring mostly in the elderly that lacks adequate treatments.

Objective: To describe our experience using dupilumab in a series of patients with BP.

Methods: This is a case series of patients from 5 academic centers receiving dupilumab for BP.

Concomitant atopic dermatitis and psoriasis - a retrospective review.

Introduction: At one time considered opposing diseases, it is now recognized that atopic dermatitis (AD) and psoriasis can coexist. There are limited data characterizing this population of patients. In this study, we characterize the population of patients diagnosed with both AD and psoriasis and summarize their response to therapy.

Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib.

Background: Existing therapies for vitiligo are limited in efficacy and can be associated with undesirable side effects. Topical Janus kinase inhibitors may offer a new therapeutic option for vitiligo.

Objective: We sought to assess the role of topical ruxolitinib 1.

Ustekinumab for treatment of cutaneous Crohn's disease.

Cutaneous Crohn disease (CD) affecting the vulva, perineum, and perianal skin, is a rare entity, which may accompany or precede gastrointestinal CD. Vulvar involvement, if untreated, may ultimately require extensive surgery including vulvectomy to gain control of the disease. Both gastrointestinal and cutaneous CD respond to biologics, which block TNF.